1. Introduction {#s1}
===============

Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) and is highly effective in improving epicardial coronary reperfusion.[@b1] However, adequate myocardial reperfusion is not achieved in a significant proportion of patients despite successful restoration of coronary blood flow; this situation correlates closely with a poor prognosis in terms of mortality and morbidity and thrombectomy devices have been developed to improve clinical outcomes.[@b2],[@b3] Different trials of manual thrombus aspiration (TA) for STEMI have yielded conflicting results and the efficacy of TA therapy for improving surrogate reperfusion markers, which translate into favorable clinical outcomes remains controversial. It is hard to explain the disparity between post-procedural surrogate outcomes and long-term clinical outcomes. TA increased the risk of stroke in the TOTAL trial (trial of routine aspiration thrombectomy with PCI *vs*. PCI alone in patients with STEMI) regardless of the length of follow-up (30 days, 180 days or 1-year). In this updated meta-analysis, we assessed individual efficacy and safety outcomes between the TA plus PCI and PCI-only arms of randomized controlled trials (RCTs).

2. Methods {#s2}
==========

2.1. Search strategy {#s2a}
--------------------

We performed a computerized literature search of PubMed, Web of Science, Embase and Cochrane Library databases on December 31, 2015. To identify relevant original peer-reviewed reports of RCTs, the following MeSH terms and keywords were used: "aspiration thrombectomy", "thrombectomy", "thrombus aspiration", "STEMI", "ST-segment elevation myocardial infarction", "myocardial infarction", "randomized", "percutaneous coronary intervention" and "PCI". Abstracts from scientific meetings of the American Heart Association, the American College of Cardiology and the European Society were screened. We performed searches without any language restriction.

2.2. Selection criteria {#s2b}
-----------------------

The studies meeting the following criteria were included: (1) RCTs; (2) the intervention group comprised patients with STEMI during PCI; and (3) the control group comprised STEMI patients treated with PCI-only. Observational studies, uncontrolled trials, review articles and case reports were excluded. We also excluded the studies of mechanical thrombectomy devices.

2.3. Definition of endpoints {#s2c}
----------------------------

The primary endpoint of this study was all-cause mortality, which was defined as death from any cause in most included trials. Deaths over different follow-up periods were also regarded as the primary endpoint. The secondary endpoints were major adverse cardiac events (MACE), recurrent infarction (RI), target vessel revascularization (TVR), stent thrombosis (ST), stroke and perfusion surrogate markers including post-procedural thrombolysis in myocardial infarction (TIMI) flow grade 3 and myocardial blush grade (MBG) 2--3.

2.4. Data extraction {#s2d}
--------------------

Data extracted from each study included study population, study name, baseline patient characteristics, intervention, study design, inclusion and exclusion criteria, and methodologic quality criteria. Discrepancies were resolved by discussion.

2.5. Statistical analysis {#s2e}
-------------------------

The individual risk of bias of each study was assessed using the Cochrane risk of bias tool. An intention-to-treat analysis was applied in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[@b4] All analyses were performed using Review Manager (RevMan) 5.3. Statistically significant heterogeneity was considered to exist in cases where *χ*^2^ test *P*-values were less than 0.05 or the *I*^2^ statistic exceeded 50%.[@b5] In the absence of heterogeneity, pooled estimates of relative risk (RR) with 95% confidence intervals (CI) were calculated using the Mantel--Haenszel (M--H) method. A random effects model for risk ratio (RR) estimation of all outcomes was employed when heterogeneity existed. Reported values are two tailed, and hypothesis testing results were considered statistically significant at *P* \< 0.05. Funnel plots and Egger\'s tests were used to assess small study effects, such as publication bias.[@b6]

3. Results {#s3}
==========

3.1. Study selection and characteristics {#s3a}
----------------------------------------

A total of 25 RCTs of 21,708 patients were included in the meta-analysis, with 10,829 patients randomized to the manual TA arm and 10,902 patients randomized to the PCI-only arm. Characteristics of the included studies are listed in [Table 1](#jgc-13-04-344-t01){ref-type="table"}.

We performed clinical outcome analyses based on different follow-up periods defined as short-term (from hospital admission to 1 month), medium-term (6--9 months) and long-term (≥1 year). Based on different follow-up periods, we calculated the RR for clinical endpoints.

3.2. Post-procedural perfusion markers {#s3b}
--------------------------------------

A significant increase in the frequency of post-procedural TIMI flow grade 3 was observed between the two groups (RR: 1.05, 95% CI: 1.02--1.09, *P* = 0.004; *P* for heterogeneity \[*P*~het~\] = 0.02, *I*^2^ = 49%; [Figure 2A](#jgc-13-04-344-g002){ref-type="fig"}). The post-procedural MBG 2--3 frequency was significantly higher in the TA plus PCI group compared with that in the PCI-only group (RR: 1.68, 95% CI: 1.40--2.00, *P* \< 0.001; *P*~het~ = 0.003, *I*^2^ = 68%; [Figure 3A](#jgc-13-04-344-g003){ref-type="fig"}). No obvious publication bias was revealed in visual funnel plots of the included studies in this updated meta-analysis of TIMI flow grade 3 and MBG 2--3 ([Figure 2B](#jgc-13-04-344-g002){ref-type="fig"}, [Figure 3B](#jgc-13-04-344-g003){ref-type="fig"}).

3.3. Mortality {#s3c}
--------------

There were no reductions in the incidences of all-cause mortality (RR: 0.91, 95% CI: 0.80--1.02, *P* = 0.11; *P*~het~= 0.67, *I*^2^ = 0; [Figure 4A](#jgc-13-04-344-g004){ref-type="fig"}) or death over the short-term (RR: 0.85, 95% CI: 0.72--1.00, *P* = 0.06; *P*~het~ = 0.93, *I*^2^ = 0; [Figure 4B](#jgc-13-04-344-g004){ref-type="fig"}), medium-term (RR: 0.90, 95% CI: 0.73--1.10, *P* = 0.30; *P*~het~ = 0.69, *I*^2^ = 0; [Figure 4C](#jgc-13-04-344-g004){ref-type="fig"}), and long-term (RR: 0.90, 95% CI: 0.80--1.02, *P* = 0.12; *P*~het~ = 0.33, *I*^2^ = 13%; [Figure 4D](#jgc-13-04-344-g004){ref-type="fig"}) follow-up periods.

3.4. MACE {#s3d}
---------

There was no statistically significant difference in the composite MACE outcomes between the two groups over the short-term (RR: 0.77, 95% CI: 0.56--1.07, *P* = 0.12; *P*~het~ = 0.98, *I*^2^ = 0; [Figure 5A](#jgc-13-04-344-g005){ref-type="fig"}), medium-term (RR: 0.94, 95% CI: 0.82--1.08, *P* = 0.38; *P*~het~ = 0.52, *I*^2^ = 0; [Figure 5B](#jgc-13-04-344-g005){ref-type="fig"}) and long-term (RR: 0.92, 95% CI: 0.82--1.02, *P* = 0.11; *P*~het~ = 0.21, *I*^2^ = 29; [Figure 5C](#jgc-13-04-344-g005){ref-type="fig"}) follow-up periods.

![Flow diagram depicting the selection of studies included in the meta-analysis.](jgc-13-04-344-g001){#jgc-13-04-344-g001}

###### Characteristics of the included studies.

  Study                        Year     Number         Design                Device                   Follow-up duration
  --------------------------- ------ ------------- --------------- -------------------------- -----------------------------------
  REMEDIA[@b7]                 2005      50/49      Single center           Diver CE                         1 mon
  DEAR-MI[@b8]                 2006      74/74      Single center            Pronto                        Hospital
  De Luca, *et al*.[@b9]       2006      38/38      Single center           Diver CE                         6 mon
  Kaltoft, *et al*.[@b10]      2006     108/107     Single center            Rescue                          1 mon
  TAPAS[@b11],[@b12]           2008     535/536     Single center            EXPORT                      1mon, 12 mon
  Chao, *et al*.[@b13]         2008      37/37      Single center            EXPORT                          6 mon
  EXPORT[@b14]                 2008     120/129      Multicenter             EXPORT                          1 mon
  VAMPIRE[@b15]--[@b18]        2008     180/175      Multicenter              TAVC             1 mon, 8 mon, 2 yrs, 3 yrs, 5 yrs
  EXPIRA[@b19],[@b20]          2009      88/87      Single center            EXPORT                      9 mon, 24 mon
  Liistro, *et al*.[@b21]      2009      55/56      Single center            EXPORT                          6 mon
  PIHRATE[@b22]                2010     100/96       Multicenter            Diver CE                         6 mon
  Ciszewski, *et al*.[@b23]    2011      67/70      Single center       Rescue/Diver CE                    Hospital
  INFUSE-AMI[@b24],[@b25]      2012     229/223      Multicenter             EXPORT                      1 mon, 12 mon
  MUSTELA[@b26]                2012     50/104       Multicenter             EXPORT                         12 mon
  TASTE[@b27],[@b28]           2014   3,621/3,623    Multicenter    Eliminate/Pronto /EXPORT             1 mon,12 mon
  TOTAL[@b29],[@b30]           2015   5,033/5,030    Multicenter             EXPORT                      6 mon, 12 mon
  Noel, *et al*.[@b31]         2005      24/26      Single center            EXPORT                        Hospital
  Lipiecki[@b32]               2009      20/24      Single center            EXPORT                        Hospital
  TROFI[@b33]                  2013      71/70       Multicenter           Eliminate                       Hospital
  NONSTOP[@b34]                2004     129/129      Multicenter             Rescue                        Hospital
  Bulum, *et al*.[@b35]        2012      30/30      Single center            EXPORT                          6 mon
  ITTI[@b36]                   2012      52/48       Multicenter         Thrombuster II                      6 mon
  Sim, *et al*.[@b37]          2013      43/43      Single center        Thrombuster II                     12 mon
  Hamza, *et al*.[@b38]        2013      25/25      Single center           Diver CE                       Hospital
  Shehata, *et al*.[@b39]      2013      50/50      Single center            EXPORT                          8 mon

![Forest plot for TIMI flow grade 3 and funnel plot for the endpoint of TIMI flow grade 3.\
PCI: percutaneous coronary in-tervention; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g002){#jgc-13-04-344-g002}

![Forest plot for myocardial blush grade 2-3 and funnel plot for the endpoint of myocardial blush grade 2-3.\
PCI: percutaneous coronary intervention; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g003){#jgc-13-04-344-g003}

3.5. RI {#s3e}
-------

The RI rate was significantly lower in the TA plus PCI arm than that in the PCI-only arm over the short-term follow-up period (RR: 0.60, 95% CI: 0.38--0.96, *P* = 0.03; *P*~het~ = 0.86, *I*^2^ = 0; [Figure 6A](#jgc-13-04-344-g006){ref-type="fig"}), while there was no significant difference in RI incidence during the medium- and long-term follow-up periods (RR: 1.00, 95% CI: 0.77--1.29, *P* = 0.98; *P*~het~ = 0.66, *I*^2^ = 0; [Figure 6B](#jgc-13-04-344-g006){ref-type="fig"}), and (RR: 0.96, 95% CI: 0.81--1.15, *P* = 0.69; *P*~het~ = 0.36, *I*^2^ = 9%; [Figure 6C](#jgc-13-04-344-g006){ref-type="fig"}), respectively.

3.6. Target vessel revascularization {#s3f}
------------------------------------

The incidence of target vessel revascularization (TVR) was not reduced by TA plus PCI therapy compared with PCI-only therapy during the short-term (RR: 0.82, 95% CI: 0.63--1.08, *P* = 0.16; *P*~het~ = 0.66, *I*^2^ = 0; [Figure 7A](#jgc-13-04-344-g007){ref-type="fig"}), medium-term (RR: 0.99, 95% CI: 0.84--1.18, *P* = 0.94; *P*~het~ = 0.88, *I*^2^ = 0; [Figure 7B](#jgc-13-04-344-g007){ref-type="fig"}), and long-term (RR: 0.98, 95% CI: 0.87--1.10, *P* = 0.70; *P*~het~ = 0.78, *I*^2^ = 0; [Figure 7C](#jgc-13-04-344-g007){ref-type="fig"}) follow-up periods.

3.7. ST {#s3g}
-------

There was no reduction in the crude ST rate in the TA plus PCI arm compared to that in the PCI-only arm (RR: 0.80, 95% CI: 0.64--1.01, *P* = 0.06; *P*~het~ = 0.91, *I*^2^ = 0; [Figure 8](#jgc-13-04-344-g008){ref-type="fig"}).

3.8. Stroke {#s3h}
-----------

The risk of stroke significantly increased in the TA plus PCI arm over the medium- and long-term follow-up (RR: 1.60, 95% CI: 1.08--2.38, *P* = 0.02; *P*~het~ = 0.57, *I*^2^ = 0; [Figure 9B](#jgc-13-04-344-g010){ref-type="fig"}), while the crude stroke rate was higher in the TA plus PCI than that in the PCI-only arm (RR: 1.43, 95% CI: 1.03--1.98, *P* = 0.03; *P*~het~ = 0.70, *I*^2^ = 0; [Figure 9C](#jgc-13-04-344-g010){ref-type="fig"}). However, there was no difference between the two arms in the incidence of early stroke in the short-term follow-up period (RR: 1.47, 95% CI: 0.97--2.21, *P* = 0.07; *P*~het~ = 0.46, *I*^2^ = 0; [Figure 9A](#jgc-13-04-344-g010){ref-type="fig"}).

![Forest plot results.\
(A): The endpoint of all-cause mortality; (B): mortality over short-term follow-up; (C): mortality over medium-term follow-up; and (D) mortality over long-term follow-up. PCI: percutaneous coronary intervention; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g004){#jgc-13-04-344-g004}

![Forest plot for MACE follow-up.\
(A): Results are short-term follow-up; (B): medium-term follow-up; and (C): long-term follow-up. MACE: major adverse cardiac events; PCI: percutaneous coronary intervention; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g005){#jgc-13-04-344-g005}

![Forest plot for RI follow-up.\
(A): Results are short-term follow-up; (B): medium-term follow-up; and (C): long-term follow-up. PCI: percutaneous coronary intervention; RI: recurrent infarction; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g006){#jgc-13-04-344-g006}

4. Discussion {#s4}
=============

This meta-analysis was performed to further evaluate the efficacy and safety of manual TA for patients with STEMI undergoing PCI. Our main findings showed that manual TA reduces the incidence of short-term recurrent infarction and did not increase the risk of stroke risk over the short-term follow-up period; however, the rates of all-cause mortality and ST were not reduced. There were no statistically differences in the rates of mortality, MACE, and TVR over short-, medium- and long-term follow-up periods and in the incidence of RI over medium- and long-term follow-up periods. These findings were derived mainly from the TASTE and TOTAL trials.[@b27]--[@b30]

The TOTAL trial, which is the largest trial conducted to date, involving 10,732 patients with STEMI during PCI, showed that manual TA improved ST-segment resolution effectively and reduced the incidence of angiographic distal embolization. However, only 10% of STEMI patients with PCI-only developed distal embolization. Other surrogate outcomes such as TIMI flow grade 3, MBG 2--3 and no reflow were not improved. Therefore, the clinical findings of the TOTAL trial suggested that TA has only a modest effect on some, but not all the surrogate post-procedural outcomes.[@b30] In contrast, our meta-analysis including the TOTAL trial data showed that post-procedural TIMI flow grade 3 and MBG 2--3 were improved by manual TA, which is consistent with the findings of previous clinical trials and meta-analyses.[@b40]--[@b42] The statistically significant heterogeneity found in post-procedural myocardial reperfusion markers is inevitable due to the different inclusion criteria and aspiration thrombectomy devices used in various clinical trials. Inverse funnel plots showed symmetrical distributions, indicating an absence of the small studies effect.

The registry-based TASTE trial showed no difference in the stroke or neurological event rates within 30 days between the TA and the PCI-only groups. Since the TOTAL trial is the largest-scale RCT of manual TA conducted to date, these data are the most robust available with respect to the effect of thrombectomy on stroke. The TOTAL trial showed that the stroke rates increased at 30 days,180 days or 1 year;[@b43] however, the current updated meta-analysis suggested additional TA for STEMI increases the stroke risk over the medium and long-term follow-up periods, while the effect on patients presenting with STEMI remains controversial during the short-term follow-up period (30 days). However, stroke is such an infrequent event that the relevance of the incidence at 30 days should be interpreted cautiously. Although, the high statistical power of the TOTAL trial allows detection of differences in the incidence of rare events, the registry-based TASTE trial that depended on discharge diagnosis codes might underestimate non-fatal events, particularly minor strokes.[@b43] Therefore, further trials are required to clarify the effects of manual TA on the stroke rate within 30 days.

4.1. Study limitations {#s4a}
----------------------

Some inherent limitations of this study should be noted. First, although a comprehensive search was conducted, publication bias may be unavoidable. Second, this meta-analysis may be influenced by differences between the included studies in individual patients, study designs, thrombectomy devices, inclusion and exclusion criteria, follow-up periods, attrition rates, and even variable definitions of some clinical endpoints. Despite these limitations, this is the largest meta-analysis conducted to date that includes recently published data of late follow-up outcomes reported from the TASTE and TOTAL trials.

![Forest plot for TVR follow-up.\
(A): Results are short-term follow-up; (B): medium-term follow-up; and (C): long-term follow-up. PCI: percutaneous coronary intervention; RR: risk ratio; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction; TVR: target vessel revascularization.](jgc-13-04-344-g007){#jgc-13-04-344-g007}

![Forest plot for ST.\
PCI: percutaneous coronary intervention; RR: risk ratio; ST: stent thrombosis; TA: thrombus aspira-tion; TIMI: thrombolysis in myocardial infarction; TVR: target vessel revascularization.](jgc-13-04-344-g008){#jgc-13-04-344-g008}

![Forest plot for stroke.\
Forest plot for stroke over short-term follow-up (A); for stroke over medium- and long-term follow-ups (B); and for the crude stroke (C). PCI: percutaneous coronary intervention; RR: risk ratio; ST: stent thrombosis; TA: thrombus aspiration; TIMI: thrombolysis in myocardial infarction.](jgc-13-04-344-g009){#jgc-13-04-344-g010}

4.2. Conclusions {#s4b}
----------------

In conclusion, among patients with STEMI, routine TA-assisted PCI can improve epicardial and myocardial parameters of reperfusion, such as TIMI flow grade 3 and MBG 2--3. Adjunctive TA for STEMI can increase the stroke risk over the medium and long-term follow-up periods, while the effects on patients presenting with STEMI remains controversial in the short-term. There is no statistically significant difference in clinical outcome endpoints of all-cause death, mortality, MACE, TVR, ST or medium- and long-term RI between in the TA plus PCI arm and the PCI-only arm; the effects of TA plus PCI might be associated with a reduction in recurrent myocardial infarction over the short-term follow-up period.
